Rodman David Malcom 4

What Happened
Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics (MLYS), was granted two equity awards on 2026-02-19: 38,400 restricted stock units (RSUs) and a 51,300-share derivative award (stock option). Both grants were awarded for no cash consideration (price $0.00), so the reported value of the transaction is $0 on the Form 4 filing — these are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: 2026-02-19; Form 4 filed 2026-02-20 (timely reporting).
• RSUs: 38,400 shares granted at $0.00. Vesting: annual installments over 4 years (1/4 each year). (Footnote F1)
• Derivative award (stock option): 51,300 underlying shares granted at $0.00. Vesting: monthly installments over 4 years (1/48 each month). (Footnote F2)
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Transaction code: A = Award/Grant. No sale or purchase executed in the open market.

Context
These awards are standard equity compensation to align executive incentives with shareholder value. The RSUs convert to company shares as they vest; the derivative award will vest gradually as options (per footnote) and would require exercise before any sale of shares. Because these were grants (not purchases or sales), they indicate compensation allocation rather than an insider buying or selling stock.